Neuroprotection In Patients Undergoing Aortic Valve Replacement
This is a multicenter randomized trial in which patients diagnosed with calcific aortic
stenosis (AS) with planned AVR will be randomized to 1) the treatment arm of the Edwards Life
Science filter and cannula or the filter as a stand alone with any cannula or 2) to the
treatment arm of the CardioGard cannula versus 3) standard care in a 1:1:1 ratio.
AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke
ARCADIA is a multicenter, biomarker-driven, randomized, double-blind, active-control, phase 3
clinical trial of apixaban versus aspirin in patients who have evidence of atrial cardiopathy
and a recent stroke of unknown cause. Eleven hundred subjects will be recruited over 2.5
years at 120 sites in the NINDS StrokeNet consortium. Subjects will be followed for a minimum
of 1.5 years and a maximum of 4 years for the primary efficacy outcome of recurrent stroke
and the primary safety outcomes of symptomatic intracranial hemorrhage and major hemorrhage
other than intracranial hemorrhage.
Powered by
SC CTSI